Van Lanschot Kempen Investment Management’s Amedisys AMED Stock Holding History

Van Lanschot Kempen Investment Management’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-262,825	Closed	-$24.1M	–	216
2024 Q2	$24.1M	Sell	262,825 -95,109	-27%	-$8.83M	0.27%	89
2024 Q1	$33M	Sell	357,934 -93,260	-21%	-$8.74M	0.41%	68
2023 Q4	$42.9M	Buy	451,194 +33,955	+8%	+$3.17M	0.6%	52
2023 Q3	$39M	Sell	417,239 -72,411	-15%	-$6.69M	0.72%	41
2023 Q2	$44.8M	Buy	489,650 +21,022	+4%	+$1.72M	0.81%	42
2023 Q1	$34.5M	Buy	468,628 +24,756	+6%	+$2.14M	0.66%	58
2022 Q4	$37.1M	Buy	443,872 +236,768	+114%	+$21.3M	1.08%	35
2022 Q3	$20M	Buy	207,104 +58,258	+39%	+$6.95M	0.81%	42
2022 Q2	$15.6M	Buy	+148,846	New	+$19M	0.56%	66

Other funds holding AMED

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Van Lanschot Kempen Investment Management's AMED Position: Q3 2024 in Review

Van Lanschot Kempen Investment Management sold out of Amedisys (AMED) in Q3 2024, closing a stake of 262,825 shares — an estimated $24.1M sold.

Van Lanschot Kempen Investment Management first reported a position in AMED in Q2 2022 and held it in 9 quarters. The position peaked at $44.8M in Q2 2023. 286 funds tracked by Wall St. Rank hold AMED as of Q3 2024.

Van Lanschot Kempen Investment Management reported no remaining Amedisys position as of Q3 2024 after selling out during the quarter.
Van Lanschot Kempen Investment Management sold 262,825 Amedisys shares in Q3 2024, an estimated $24.1M.
Van Lanschot Kempen Investment Management first reported a position in Amedisys in Q2 2022 and held it in 9 quarters.
Van Lanschot Kempen Investment Management's Amedisys position peaked at $44.8M in Q2 2023.
286 funds tracked by Wall St. Rank held Amedisys as of Q3 2024.

Based on Van Lanschot Kempen Investment Management's 13F filing for Q3 2024, filed 14 Nov 2024.